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SUMMARY AT A GLANCE
This review describes evidence supporting a pathogenic role for tumour necrosis factorrelated weak inducer of apoptosis (TWEAK) in human and experimental lupus nephritis. Current understanding of TWEAK is integrated with known mechanisms of renal inflammation and fibrosis. This is highly relevant given early stage clinical studies with anti-TWEAK monoclonal antibodies.
ABSTRACT:
As one of the manifestations of patients with systemic lupus erythematosus, lupus nephritis (LN) has high morbidity and mortality. Although the explicit mechanism of LN remains to be fully elucidated, there is increasing evidence to support the notion that tumour necrosis factor-related weak inducer of apoptosis (TWEAK), acting via its sole receptor, fibroblast growth factorinducible 14 (Fn14), plays a pivotal role in such pathologic process. TWEAK/Fn14 interactions occur prominently in kidneys of LN, inducing inflammatory responses, angiogenesis, mesangial proliferation, filtration barrier injuries, renal fibrosis, etc. This review will specify the important roles of TWEAK/Fn14 pathway in the pathogenesis of LN with experimental data from cellular and animal models. Additionally, the raised levels of urinary and serum soluble TWEAK correlate with renal disease activity in patients with LN. The neutralizing antibodies targeting TWEAK or other approaches inhibiting TWEAK/Fn14 signals can attenuate renal damage in the murine lupus models. Therefore, to focus on TWEAK/Fn14 signalling may be promising in both clinical evaluation and the treatment of patients with LN.
As an autoimmune disease, systemic lupus erythematosus (SLE) is featured by the occurrence of autoantibodies to nuclear self-antigens, which further induce multiple organ damage. Implicated to be consequence of anti-DNA IgG deposition, 1 renal involvement or so called lupus nephritis (LN), is a typical internal complication of SLE patients. Approximately 60% of SLE patients have renal abnormalities, 25-50% of patients manifest clinical renal disease when they were diagnosed. 2 Infection, LN, lupus encephalopathy, and cardiovascular disease are the top four death causes for patients with SLE. 3 The pathogenesis of LN is complicated. It is initiated in most cases by the glomerular deposition of autoantibodies and other immune complexes or complements. While then the generation of proinflammatory cytokines, infiltration of inflammatory cells, cell proliferation, and vascular rarefaction injuries do harm to glomeruli via multiplex mechanisms, and eventually cause tubulointerstitial fibrosis and glomerulosclerosis. 4 Tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a cytokine with important functions. Binding to fibroblast growth factor-inducible 14 (Fn14), its sole receptor, TWEAK mediates various biological activities, involving activation of cell growth, migration or death, induction of vasculitis and angiogenesis, production of proinflammatory cytokines, and promotion of fibrogenic responses. [5] [6] [7] [8] In normal tissues, TWEAK and Fn14 expression is relatively low. However, under the circumstances of acute or chronic inflammatory processes, Fn14 expression increases significantly while TWEAK levels increase accordingly. Transient activation of TWEAK/Fn14 pathway is suggested in physiologic repairing and tissular regeneration; while over-activation may launch pathologic responses under the conditions of chronic impairment and contribute to progressive tissular injuries and deterioration. 9, 10 Recently, there has been increasing evidence supporting that TWEAK/Fn14 signals play a pivotal role in the pathologic processes of LN. In this paper, we summarize these findings with an emphasis on predictive and therapeutic implication of TWEAK/Fn14 pathway in LN.
TWEAK/FN14 ACTIVATION AMPLIFIES RENAL INFLAMMATION
TWEAK is broadly expressed in multifarious inflammatory tissues, but predominantly by immune cells such as macrophages. 7, 11, 12 TWEAK protein has two forms: membrane or soluble TWEAK, the latter of which is derived from membrane TWEAK through proteolytic processing. 13 Both soluble and membrane TWEAK activates the sole receptor, Fn14. 14 Fn14
is expressed by renal intrinsic cells, including podocytes, mesangial cells, glomerular endothelial cells, and tubular cells. 15, 16 Under normal conditions, the TWEAK and Fn14 levels are relatively low in kidney tissues. However, in human LN, both glomeruli and tubules highly express mRNA of TWEAK and Fn14. 17 In the lupus-prone model (BXSB strain), the mRNA levels of TWEAK are upregulated during early stage of renal disease. 18 In MRL/lpr lupus-prone mice and murine model of nephrotoxic serum nephritis (antibody-induced nephritis), Fn14 displays higher level in glomeruli, in contrast with control mice that have no renal involvement. 15, 16 Renal TWEAK/Fn14 activation triggers the generation of multiple proinflammatory cytokines that may initiate the pathologic progresses of LN. TWEAK/Fn14 signalling functions via extracellular signal-regulated kinase 1/2 (ERK1/2), mitogenactivated protein kinases (MAPK), phosphoinositide 3-kinase (PI3K)/Akt, Janus kinase, p38, and also canonical or noncanonical nuclear factor-κB (NF-κB). [19] [20] [21] [22] As a result of TWEAK/Fn14 activation, proinflammatory cytokines including regulated upon activation normal T cell expressed and secreted (RANTES), interferon-γ (IFN-γ)-induced protein 10 (IP-10), and monocyte chemotactic protein-1 (MCP-1) are expressed by human kidney cells or in kidneys of the mice with nephrotoxic serum nephritis. 15, 23 In tubular cells, the expression of additional inflammatory cytokines like chemokine (C-C motif) ligand 19 (CCL19), CCL21, and chemokine (C-X-C motif) ligand 16 (CXCL16) are induced by TWEAK activation via NF-kB pathway. 24, 25 Moreover, in tubular epithelial cells, TWEAK activates epidermal growth factor receptor (EGFR) signals through increasing EGFR phosphorylation, which further triggers the production of cytokines including interleukin 6, intracellular adhesion molecule-1, IP-10, and CCL20. 26 These are shown in Figure 1 .
The overexpression of inflammatory cytokines may initiate and exacerbate local inflammation in LN. RANTES, MCP-1, and IP-10 recruit monocytes and activated T cells, which are instrumental in the pathogenesis of LN.
27 RANTES accelerates renal disease in MRL/lpr mice, whereas MCP-1 deletion dramatically decreases infiltration of T cells and macrophages, hypercellularity and sclerosis of glomeruli, vascular injuries, and crescent formation. 8 As a T cell chemoattractant chemokine, CXCL16 can be upregulated by TWEAK in tubular epithelium, further contributing to tubulointerstitial inflammation in kidneys. 25 Moreover, TWEAK triggers monocytes differentiating into macrophages and migrating into renal tissues. 24 In MRL/lpr mice, knockout of Fn14 reduces renal macrophage and T cell infiltration. 16 Therefore, TWEAK/Fn14 activation exacerbates inflammatory responses in LN through promoting cytokine production and inflammatory cell infiltration.
TWEAK/FN14 ACTIVATION MODULATES CELL FATE IN KIDNEYS
As a tissue repairing mechanism, glomerular mesangial cells can proliferate early during the injuries induced by immune complex deposition. Both in vitro and in vivo, TWEAK/Fn14 activation enhances proliferation of mesangial cells. 23 Moreover,
Fn14 deficiency decreases proliferation of mesangial cell in murine model of chronic graft versus host disease. 27 Furthermore, TWEAK blockade reduces both proliferation of mesangial cells and periodic acid Schiff staining of glomeruli in the nephrotoxic serum nephritis model. 15 In MRL/lpr mice, Fn14 deficiency can induce amelioration of renal injuries, which is mirrored by reduction of proteinuria and remarkable attenuation of mesangial proliferation. 16 TWEAK also has proliferative effect on renal tubules in vivo and on tubular cells in vitro.
28 TWEAK induces proliferation of tubular cells requiring activation of MAPK, ERK1/2, p38, PI3K/Akt, and NF-κB pathways. 28 In the mice accepting unilateral nephrectomy, the remnant kidneys highly express Fn14 in tubular cells. 28 Systemic administration of exogenous TWEAK has remarkable proliferative effect on tubular cells in the remnant kidneys, whereas TWEAK-knockout mice have reduced kidney size and proliferating tubular cells. 28 Moreover, TWEAK can promote both human umbilical vein endothelial cells (HUVEC) and smooth muscle cells to proliferate. 29 Due to its upregulation effect on Fn14 expression, fibroblast growth factor-2 can enhance proliferation of HUVEC under TWEAK stimulation. 29 Actually, TWEAK/Fn14 activation exhibits the proinflammatory, proliferative, and pro-apoptotic effect depending on the cell types and the microenvironments. 28 TWEAK/Fn14 signalling can cause cell death in LN. TWEAK-induced death of renal cells correlates with other inflammatory cytokines such as IFN-γ, which synergistically induces death of mesangial cells. 30 Along with TNF-α and IFN-γ, TWEAK can also activate tubular cell apoptosis. 31 Furthermore, TWEAK can induce death of glomerular endothelial cells and podocytes, which is prevented upon Fn14 siRNA transfection. 16 Fn14 knockout can also attenuate the decrease of podocytes in glomeruli in MRL/lpr mice. 16 TWEAK/Fn14 activation induces cell death involving both caspase-dependent and -independent apoptosis. 32 Furthermore, TWEAK can induce cell death through cathepsin B-dependent necrosis mechanism. 21 
TWEAK/FN14 ACTIVATION INJURIES FILTRATION BARRIER
The maintenance of integrity of renal filtration barrier is important for normal kidneys. However, TWEAK/Fn14 activation can damage the function of renal filtration barrier. In MRL/lpr mouse strain, the number of podocytes decreases significantly in glomeruli from wild-type mice when compared to that from Fn14-knockout mice. 16 Furthermore, the reduction of glomerular nephrin and podocin expression in mice can be partially recovered upon Fn14 deficiency. 16 Interestingly, there is no difference in serum titre of anti-DNA IgG between wild-type and Fn14-knockout mice, demonstrating that Fn14 deficiency protects MRL/lpr mice from LN through preserving glomerular filtration barrier but not reducing renal anti-DNA IgG deposition. 16 The in vitro effect of TWEAK/Fn14 activation on glomerular filtration barrier was verified by the facts that TWEAK induces death of glomerular endothelial cells and podocytes, and prominently increases the permeability for fluorescein isothiocyanate-labelled bovine serum albumin and dextran through endothelial cell or podocyte monolayers. 16 Moreover, the transfection of Fn14 siRNA can protect against the increase in renal cell death and barrier permeability upon TWEAK stimulation. Additionally, TWEAK/Fn14 activation decreases cellular expression of junctional proteins including ZO-1, podocin, and nephrin, which are responsible for maintaining the function of slit diaphragms. 16, 33 These findings strikingly confirm that TWEAK/Fn14 activation contributes to the glomerular filtration barrier injuries in LN.
TWEAK/FN14 ACTIVATION PROMOTES RENAL FIBROSIS
It is well known that fibrotic lesions such as interstitial and vascular fibrosis as well as glomerulosclerosis are strongly associated with poor outcome in LN. There is much evidence supporting fibrogenic effect of TWEAK/Fn14 signals on the kidneys, which is the downstream consequence related to proinflammatory activities of these signals. 15, [23] [24] [25] [26] Meanwhile, TWEAK regulates matrix metalloproteinases and their tissue inhibitors in myopathies, and is associated with the intestinal damage that links to extracellular matrix-related proteins. 34 The protein levels of collagen I, α-smooth muscle actin, and extracellular matrix components that can gradually replace normal parenchyma and even destruct tissular function when overproduced, increase in the kidneys of MRL/lpr mice, and such increase can be reversed by lentivirus-TWEAK-shRNA treatment. 35 Transforming growth factor-β (TGF-β) signalling, enhanced by proinflammatory cytokines, is a central inducer A TWEAK/Fn14 pathway in lupus nephritis of renal fibrosis. 36 TWEAK-mediated upregulation of TGF-β signalling can promote kidney remodelling in LN; as the downstream of TWEAK-TGF-β pathway, the phosphorylation of p38 MAPK and Smad2, may contribute to TWEAK-TGF-β induced fibrogenesis.
35
Indirectly, TWEAK may mediate fibrosis via enhancing proliferation of cells such as mesangial cells, which are the main source of glomerular production of extracellular matrix. 6, 24 TWEAK activates Ras GTPase in kidney fibroblasts cultured in vitro, further promoting cell proliferation and migration that are mediated by extracellular signal-regulated kinases and Ras signals. 37 The two processes can expand the pool of fibroblasts, and have been verified by the functional studies using a model of persistent unilateral ureteral obstruction. 28, 38 In contrast, TWEAK also affect fibroblasts directly through decreasing the production of extracellular matrix in Ras-and p38 MAPKdependent manners. 37 Additionally, TWEAK exerts proinflammatory activities in fibroblasts via NF-κB pathway, which can be mirrored in TWEAK-overexpressing mice that exhibit renal fibroblast proliferation and fibrosis.
37
Significantly, apart from proliferation of resident fibroblasts, multiple parental lineages that include endothelial cells, tubular epithelial cells, and pericytes can also derive into fibrogenic fibroblasts.
39,40 TWEAK may control production of CCL21, a chemokine involving in recruitment of fibrocytes. 41 Moreover, one potent anti-renal fibrosis agent, antiaging hormone Klotho, is downregulated by TWEAK in kidneys. 42 Hence, TWEAK/Fn14 signalling engenders a pro-fibrogenic effect on kidneys through modulating different processes and eliciting various actions on diverse cells (Fig. 2) .
SOLUBLE TWEAK EMERGES AS A MARKER OF LN DISEASE ACTIVITY
Recently, soluble TWEAK in urine was analyzed for monitoring disease activity of LN. The levels of urinary TWEAK (uTWEAK) in lupus patients that present active renal disease are higher than those who had non-active renal involvement. 43 Moreover, the uTWEAK levels significantly associate with renal disease activity that is assessed by the renal SLE disease activity index (SLEDAI) scores. 44 Furthermore, LN patients undergoing a renal flare have higher levels of uTWEAK than stable individules. 43 Similarly, the uTWEAK levels have a positive relationship with the tSLEDAI and rSLEDAI scoring systems, and peak when renal disease flares. 45 In addition, the increasing uTWEAK levels correlate with upregulated renal expression of TWEAK. 46 The serum levels of TWEAK in SLE patients are markedly higher when compared to healthy donors, in spite of SLEDAI scores in patients. 47 Additionally, the serum levels of TWEAK fluctuates with the MCP-1 and IP-10 levels in sera. Estrogen-induced TWEAK expression in peripheral blood mononuclear cells accelerates the progression of LN. 48 Overexpression of TWEAK in peripheral blood mononuclear cells is related with proteinuria and disease activity in patients with SLE. 49 All of this evidence suggests that TWEAK could a biomarker candidate reflecting both renal involvement and disease activity in SLE patients.
TARGETING TWEAK/FN14 PATHWAY AS A THERAPEUTIC STRATEGY
Since TWEAK/Fn14 pathway is essential for the pathogenesis of LN, to block TWEAK/Fn14 signalling in kidneys becomes a promising therapeutic strategy. In chronic graft versus host disease model, a neutralizing anti-TWEAK mAb dramatically decreases proteinuria and downregulates renal proinflammatory cytokines including RANTES, IP-10, MCP-1, and IL-6. 27 Also, in the murine nephrotoxic serum nephritis model, anti-TWEAK mAb leads to improvement of renal histopathology (inflammation, IgG deposition, resident cell proliferation, and fibrosis) as well as reduction of proteinuria but without effect on titres of mouse anti-rabbit IgG. 15 With treatment of lentivirus-control shRNA or vehicle solution, MRL/lpr mice present remarkable proteinuria and serious changes of renal histopathology, whereas the treatment of lentivirus-TWEAKshRNA reverses these consequences and downregulates renal protein levels of p-p38 MAPK, TGF-β1, p-Smad2, α-smooth muscle actin, and collagen I. 35 Fn14 deficiency has been introduced into several murine strains of LN, and leads to prominent amelioration of renal disease. In the models of nephrotoxic serum nephritis, chronic graft versus host disease, and MRL/lpr lupus-prone mice, Fn14 knockout evidently attenuates proteinuria and renal histology. 15, 16, 27 An interesting phenomenon in these models is that Fn14 deficiency does not alter serum titres of pathological antibodies such as anti-DNA IgG or mouse anti-rabbit IgG, demonstrating that Fn14 blockade protects against LN via locally reducing inflammation and maintaining filtration barrier, but not systemically inhibiting the production of pathological antibodies. 15 
